Allergy Therapeutics (LON:AGY) - Potential to boost PQ sales
Oct 02nd 2012 - Edison Investment Research today published a report on Allergy Therapeutics (AGY.L, LSE:AGY, LON:AGY) entitled "Potential To Boost PQ Sales". In summary, the report says:
Allergy Therapeutics intends to become a top-three player in the global AIT (allergy immunotherapy) market; recent and upcoming regulatory catalysts should support this, driving future revenue growth. The FDA clinical hold lift on Pollinex Quattro (PQ) Grass permits Allergy to go ahead with US plans to secure a partner within the next 12 months. PEI feedback (and potential approval) of the German PQ Grass MAA is expected in Q412, which will allow commercial marketing in Germany and the initiation of filings across Europe under the Mutual Recognition Procedure (MRP).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
